OPTIMIZATION OF FEEDING IN CHILDREN WITH COLON AGANGLIOSIS RECEIVING A PROBIOTIC THERAPY

Abstract

The article discusses an issue of prescribing probiotics and enteral  nutrition products in children with colon agangliosis. In a prospective  study, it was found, that the use of a qualitative stool test for  Clostridium difficile toxins A and B during pre-operative period of Hirschsprung disease helps to determine the tactics for antibacterial  therapy, and the integrated use of a probiotic preparation and an enteral nutrition product in the perioperative period plays an important role in the prevention of severe complications, such as enterocolitis and antibiotic-associated diarrhea.

Keywords

children / probiotics / colon agangliosis / Hirschsprung disease / vancomycin / Clostridium difficile / high-protein / high-calorie enteral nutrition / enterocolitis / antibiotic-associated diarrhea

References

[1] 1. Hirschsprung H. Stuhlträgheit Neugeborener in Folge von Dilation und Hypertrophie des Kolons. Jahrbuch für Kinderheilkunde. 1888.

[2] 2. Pastor A. C., Osman F., Teitelbaum D. H., et al. Development of a standardized definition for Hirschsprung’s-associated enterocolitis: a Delphi analysis. J Pediatr Surg. 2009;44 (1):251–256; doi: 10.1016/j.jpedsurg.2008.10.052.

[3] 3. Pini-Prato A., Rossi V., Avanzini S., Mattioli G., Disma N., Jasonni V. Hirschsprung’s disease: what about mortality? Pediatr Surg Int. 2011;27:473–478.

[4] 4. Frykman P. K., Short S. S. Hirschsprung-Associated Enterocolitis: Prevention and Therapy. Seminars in pediatric surgery. 2012;21 (4):328–335; doi:10.1053/j.sempedsurg.2012.07.007.

[5] 5. Vieten D., Spicer R. Enterocolitis complicating Hirschsprung’s disease. Semin Pediatr Surg. 2004;13 (4):263–272; doi: 10.1053/j.sempedsurg.2004.10.014.

[6] 6. Surana R., Quinn F., Puri P. Evaluation of risk factors in thedevelopment of enterocolitis complicating Hirschsprung’s disease.Pediatr Surg Int. 1994;9:234–236.

[7] 7. Levin D. N., Marcon M. A., Rintala R. J., et al. Inflammatory bowel disease manifesting after surgical treatment for Hirschsprung disease. J Pediatr Gastroenterol Nutr. 2012;55 (3):272–277; doi: 10.1097/MPG.0b013e31824f617a.

[8] 8. Pastor A. C., Osman F., Teitelbaum D. H., et al. Development of a standardized definition for Hirschsprung’s-associated enterocolitis: a Delphi analysis. J Pediatr Surg. 2009;44 (1):251–256; doi: 10.1016/j.jpedsurg.2008.10.052.

[9] 9. Teitelbaum D. H., Qualman S. J., Caniano D. A. Hirschsprung’s disease. Identification of risk factors for enterocolitis. Ann Surg. 1988;207 (3): 240–244; doi: 10.1097/00000658‑198803000‑00003.

[10] 10. Slattery J., MacFabe D. F., Frye R. E. The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood. Clinical Medicine Insights Pediatrics. 2016; 10:91–107; doi:10.4137/CMPed.S38338.

[11] 11. Xiaolin Wang, Zhi Li, Zhilin Xu, Zhongrong Wang, Jiexiong Feng. Probiotics prevent Hirschsprung’s disease-associated enterocolitis: a prospective multicenter randomized controlled trial. Int J Colorectal Dis (2015) 30: 105–110; doi:10.1007/s00384‑014‑2054‑0.

[12] 12. Johnston B. C., Ma S. S., Goldenberg J. Z., Thorlund K., Vandvik P. O., Loeb M. et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157:878–888; http://dx.doi.org/10.7326/0003‑4819‑157‑12‑201212180‑00563.

[13] 13. Shen D. H., Shi C. R., Chen J. J., et al. Detection of intestinal bifidobacteria and lactobacilli in patients with Hirschsprung’s disease associated enterocolitis. World J Pediatr. 2009;5 (3): 201–205; doi: 10.1007/s12519‑009‑0038‑x.

[14] 14. Herek O. Saccharomyces boulardii: a possible addition to the standard treatment and prophylaxis of enterocolitis in Hirschsprung’s disease? Pediatr Surg Int. 2002;18 (5-6):567; doi: 10.1007/s00383‑002‑0742‑2.

[15] 15. Gosain A., Brinkman A. S. Hirschsprung’s Associated Enterocolitis. Current opinion in pediatrics. 2015;27 (3):364–369.

[16] 16. Wang Q., Dong J., Zhu Y. Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very lowbirth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. Journal of Pediatric Surgery,Volume47, Issue1,241–248.

[17] 17. Chong P. P., Chieng D. C., Low L. Y., et al. Recurrent candidaemia in a neonate with Hirschsprung’s disease: fluconazole resistance and genetic relatedness of eight Candida tropicalis isolates. J Med Microbiol. 2006;55 (Pt 4):423–428; doi: 10.1099/jmm.0.46045–0.

[18] 18. De Filippo C., Pini-Prato A., Mattioli G., et al. Genomics approach to the analysis of bacterial communities dynamics in Hirschsprung’s disease-associated enterocolitis: a pilot study. Pediatr Surg Int. 2010; 26 (5):465–471; doi: 10.1007/s00383‑010‑2586‑5.

[19] 19. Morinville V., McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children // Can J Gastroenterol. 2005. Vol. 19. № 8. Р. 497–501.

[20] 20. Сытьков В. В., Поддубный И. В., Козлов М. Ю. Оптимизация периоперационной антибактериальной терапии при реконструктивных операциях по поводу аганглиоза толстой кишки у детей. Вопросы современной педиатрии. 2016. Т. 15. № 4. С. 352–357 (Sytkov V. V., Poddubny I. V., Коzlov M. Y. Optimizing Perioperative Antibacterial Therapy in Reconstructive Surgery for Colonic Agangliosis in Children. Voprosi sovremennoy pediatrii. 2016;15 (4):352–357. (In Russ.) DOI:10.15690/vsp.v15i4.1585).

RIGHTS & PERMISSIONS

Sytkov V.V., Poddubny I.V., Borovik T.E., Yatsyk S.P., Dyakonova E.Y., Kozlov M.Y., Malashenko A.S., Okulov E.A.